Induction of liver cytochrome P450 1A2 expression by flutamide in rats

被引:5
作者
Wang, HX
Liu, X
Xu, CJ
Ma, XC
Long, JE
Li, D [1 ]
机构
[1] Fudan Univ, Sch Basic Med Sci, Inst Mol Virus, Shanghai 200031, Peoples R China
[2] Fudan Univ, Sch Pharm, Dept Pharmacol, Shanghai 200032, Peoples R China
[3] Chinese Acad Sci, Shanghai Inst Mat Med, Inst Biol Sci, State Key Lab Drug Res, Shanghai 200031, Peoples R China
关键词
flutamide; cytochrome P450 1A2; induction;
D O I
10.1111/j.1745-7254.2005.00211.x
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Aim: To investigate the modulation of liver cytochrome P450 1A2 (CYP1A2) expression by giving flutamide to adult rats. Methods: Rats were given 50, 100, and 200 mg/kg po of flutamide for 2 weeks. Liver CYP1A2 mRNA was measured using reverse transcription-polymerase chain reaction. CYP 1A2 protein was detected using immunoblotting. CYP1A2 activity was assayed using high performance liquid chromatography, with caffeine as the CYP1A2 substrate. Results: CYP1A2 mRNA levels after flutamide treatment at 100 mg/kg and 200 mg/kg were, respectively, 1.86 and 3.11-fold higher than those of the control. Correspondingly, CYP1A2 protein increased 1.78 and 2.89-fold and CYP1A2 activity increased approximately 1.65 and 2.83-fold, respectively, relative to controls. Flutamide treatment at 50 mg/kg had no significant effect on CYP1A2 mRNA, protein, or enzyme activity. Conclusion: Giving rats flutamide induced liver CYP1A2 expression in a dose-dependent manner.
引用
收藏
页码:1382 / 1386
页数:5
相关论文
共 28 条
[1]   Flutamide-induced hepatic dysfunction in relation to steady-state plasma concentrations of flutamide and its metabolites [J].
Aizawa, Y ;
Ikemoto, I ;
Kishimoto, K ;
Wada, T ;
Yamazaki, H ;
Ohishi, Y ;
Kiyota, H ;
Furuta, N ;
Suzuki, H ;
Ueda, M .
MOLECULAR AND CELLULAR BIOCHEMISTRY, 2003, 252 (1-2) :149-156
[2]   Fulminant liver failure associated with flutamide therapy for hirsutism [J].
Andrade, RJ ;
Lucena, MI ;
Fernández, MC ;
Suárez, F ;
Montero, JL ;
Fraga, E ;
Hidalgo, F .
LANCET, 1999, 353 (9157) :983-983
[3]  
ANJUMATH S, 1997, DURG METAB DISPOS, V25, P1298
[4]  
BONARD M, 1975, EUR UROL, V2, P24
[5]  
Boobis A R, 1995, Princess Takamatsu Symp, V23, P134
[6]  
BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
[7]   HUMAN CYTOCHROME P-450PA (P-450IA2), THE PHENACETIN O-DEETHYLASE, IS PRIMARILY RESPONSIBLE FOR THE HEPATIC 3-DEMETHYLATION OF CAFFEINE AND N-OXIDATION OF CARCINOGENIC ARYLAMINES - (AROMATIC-AMINES HETEROCYCLIC AMINES CARCINOGEN METABOLISM) [J].
BUTLER, MA ;
IWASAKI, M ;
GUENGERICH, FP ;
KADLUBAR, FF .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1989, 86 (20) :7696-7700
[8]   TREATMENT OF BENIGN PROSTATIC HYPERTROPHY WITH FLUTAMIDE (SCH 13521) - PLACEBO-CONTROLLED STUDY [J].
CAINE, M ;
PERLBERG, S ;
GORDON, R .
JOURNAL OF UROLOGY, 1975, 114 (04) :564-568
[9]  
Casley WL, 1999, DRUG METAB DISPOS, V27, P1375
[10]   Microarray analysis of changes in renal phenotype in the ethylene glycol rat model of urolithiasis: potential and pitfalls [J].
Chen, DHC ;
Kaung, HLC ;
Miller, CM ;
Resnick, MI ;
Marengo, SR .
BJU INTERNATIONAL, 2004, 94 (04) :637-650